Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

Expert Rev Anti Infect Ther. 2014 Oct;12(10):1171-8. doi: 10.1586/14787210.2014.948847. Epub 2014 Aug 13.

Abstract

CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

Keywords: BK virus; Brincidofovir; CMX001; JC virus; adenovirus; cytomegalovirus; dsDNA virus; molluscum; orthopoxvirus; vaccinia virus.

MeSH terms

  • Adenoviridae / drug effects
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Cytomegalovirus / drug effects
  • Cytosine / analogs & derivatives*
  • Cytosine / chemistry
  • Cytosine / pharmacology
  • Cytosine / therapeutic use
  • DNA Virus Infections / drug therapy*
  • Humans
  • Microbial Sensitivity Tests
  • Molluscum contagiosum virus / drug effects
  • Organophosphonates / chemistry
  • Organophosphonates / pharmacology
  • Organophosphonates / therapeutic use*
  • Orthopoxvirus / drug effects
  • Polyomavirus / drug effects

Substances

  • Antiviral Agents
  • Organophosphonates
  • brincidofovir
  • Cytosine